Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research development, manufacture and commercialization of vaccines that protect against human infectious diseases.
While the young company is already renowned for being a leading provider of vaccines in China, Sinovac Biotech is making even greater strides in the market. One of the major advances made by the company came today when Sinovac announced that it has received the Good Manufacturing Practice (GMP) certification for its recently opened filling and packaging production facility. The certificate of compliance has a five-year term and was issued by the State Food and Drug Administration (SFDA) following a site inspection.
The GMP certification provides for an overall annual production capacity of 20 million doses, with the capability to produce up to 40 million doses through reasonable scheduling of production activities. This production milestone ensures that Sinovac can fully meet increasing market demand and potential production increases for its commercialized products.
Sinovac Biotech is led by Weidong Yin who serves as the company Chairman, President and CEO. When asked about this certification, Weidong commented, ”The receipt of the GMP certification and the operation of the state-of-the-art filling and packaging facility provide the foundation for the further development of Sinovac. We are well positioned to increase output to meet increasing market demand and ultimately achieve sales growth. More importantly, the expanded production capacity should enable Sinovac to supply greater amount of vaccines, which is in line with our mission to eliminate human diseases.”